arrow
J

Jeph Herrin

Yale School of Medicine
H指数:62
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of GLP-1 receptor agonists, SGLT 2 inhibitors, DPP-4 inhibitors, and sulfonylureas with incident cancer in type 2 diabetes

GLP-1受体激动剂、SGLT 2抑制剂、DPP-4抑制剂和磺脲类药物与2型糖尿病患者新发癌症的关联

2026-08-170
OAAI
Cardiovascular Effects of Alogliptin, Linagliptin, Saxagliptin, and Sitagliptin: A Target Trial Emulation of a Comparative Effectiveness Study

阿格列汀、利格列汀、沙格列汀和西格列汀的心血管效应:一项比较疗效研究的靶试验模拟研究

2026-04-080
PRE
Timeliness of Antiresorptive Consolidation After Anabolic Therapy for Primary Fracture Prevention: A U.S. Cohort Study

抗吸收巩固的及时性:用于一级骨折预防的合成代谢疗法后的美国队列研究

2026-03-040
PRE
Effect of a Symptom Surveillance and Collaborative Care Intervention on Palliative Care Utilization

症状监测与协作护理干预对姑息治疗利用的影响

2026-03-010
PRE
Electronic health record-facilitated symptom surveillance and collaborative care intervention in oncology (E2C2): a cluster-randomised, population-level, stepped-wedge, pragmatic trial

电子健康记录辅助的症状监测和协作护理干预在肿瘤学中的应用(E2C2):一项集群随机、群体水平、阶梯式楔形、实用性试验

2025-12-010
PRE
Comparative effectiveness of GLP-1 receptor agonists on cardiovascular outcomes among adults with type 2 diabetes and moderate cardiovascular risk: emulation of a target trial

GLP-1受体激动剂在具有中度心血管风险的2型糖尿病成人中对心血管结局的相对有效性:目标试验的模拟研究

2025-09-200
OAAI
Comparative Risk of Adverse Pancreatic Events with GLP-1 Receptor Agonists, SGLT2 Inhibitors, DPP4 Inhibitors, and Sulfonylureas among Adults with Type 2 Diabetes at Moderate Cardiovascular Disease Risk

GLP-1受体激动剂、SGLT2抑制剂、DPP4抑制剂和磺脲类药物在具有中度心血管疾病风险的2型糖尿病成人中不良胰腺事件的比较风险

2025-09-110
PRE
Risk of Sight-Threatening Diabetic Retinopathy With GLP-1 RA Use in Routine Clinical Practice: Comparative Effectiveness of Semaglutide, Dulaglutide, Liraglutide, and Exenatide

使用GLP-1 RA治疗在常规临床实践中导致视力威胁性糖尿病视网膜病变的风险:司美格鲁肽、度拉糖肽、利拉鲁肽和艾塞那肽的疗效比较

2025-08-060
PRE
Mediators of Racial Inequities in Non-Small Cell Lung Cancer Care

非小细胞肺癌护理中种族不平等的介导因素

2025-03-070
OAAI